Demystify drug coverage. Learn the business and clinical reasons why some medications are covered by insurance and others ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of privacy issues from the collecting of sensitive health histories and the ...

Investing.com - TD Cowen has lowered its price target on Novo Nordisk (NYSE: NVO) to $70.00 from $105.00 while maintaining a Buy rating on the stock. The new target sits within the broader analyst ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

This week, medication savings platform GoodRx announced a partnership with Novo Nordisk – the company behind Ozempic and Wegovy – to offer the drugs at nearly half price for self-paying patients.

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

GoodRx reports that insurance formularies are shrinking, leading to fewer covered medications and increased restrictions on ...

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official ...